胃肠道弥漫大B细胞淋巴瘤的治疗及相关潜在预后因素的研究进展

Advances in treatment of gastrointestinal diffuse large B-cell lymphoma and related po-tential prognostic factors

弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中最常见类型,是成年人发病率较高的中高度恶性淋巴瘤,在临床表现上多为侵袭性病程,多表现为无痛性进行性肿大的淋巴结,但也可表现为原发于结外,其中胃肠道是DLBCL最好发的结外部位,虽然关于DLBCL的治疗已渐规范化,但由于胃肠道DLBCL起病隐匿,临床症状不典型,其治疗尚无统一的标准,且影响其生存的预后因素较多,因此为提高临床对此疾病的认识,以便因人而异的制定治疗方案及评估其生存预后,现对其治疗方式的选择及影响预后的相关因素的最新进展进行综述。

Diffuse large B-cell lymphoma(DLBCL)is the most common type of non-Hodgkin's lymphoma(NHL).It is a medium to high-grade malignant lymphoma with a high incidence in adults.Most of the clinical man-ifestations are invasive disease course,and most of them are painless and progressively enlarged lymph nodes,but they can also be expressed outside the nodules.Among them,the most likely site of DLBCL is the gastrointestinal tract.Al-though the treatment of DLBCL has gradually been standardized,because of the hidden onset of the gastrointestinal tract,the clinical symptoms are not typical,there is no unified standard for its treatment,and there are many factors af-fecting its survival prognosis,so in order to improve the clinical understanding of this disease in order to formulate treatment plans and evaluate the survival prognosis for different people,we now review the selection of treatment meth-ods and the latest progress of related factors that affect the prognosis.